AstraZeneca Receives the CHMP Positive Opinion for Camizestrant to Treat Advanced Breast Cancer

Why It Matters

The CHMP opinion accelerates a potential new treatment option for a subset of breast‑cancer patients who have limited alternatives after endocrine resistance, promising longer disease control and improved survival outcomes.

Key Takeaways

• Camizestrant reduced progression risk by 56% versus AI combo
• Median PFS extended to 16 months, up from 9.2 months
• CHMP positive opinion clears path for EU market entry
• Trial enrolled 315 ESR1‑mutated HR+/HER2‑ advanced breast cancer patients
• Regulatory reviews now ongoing in United States and Japan

Pulse Analysis

ESR1 mutations drive resistance to aromatase inhibitors in estrogen‑receptor‑positive, HER2‑negative breast cancer, leaving patients vulnerable after first‑line endocrine therapy. Camizestrant, an oral selective estrogen receptor degrader, directly targets the mutant receptor, restoring hormonal control while sparing normal tissue. By pairing it with a CDK4/6 inhibitor—palbociclib, ribociclib, or abemaciclib—the regimen tackles both the proliferative signaling and the hormonal driver, a strategy that aligns with the evolving precision‑oncology paradigm.

The SERENA‑6 phase‑III trial enrolled 315 patients with advanced disease and confirmed ESR1 mutations, comparing camizestrant plus a CDK4/6 inhibitor against the standard aromatase‑inhibitor (anastrozole or letrozole) plus CDK4/6 inhibitor backbone. Results showed a 56% relative risk reduction for disease progression or death, extending median progression‑free survival to 16 months versus 9.2 months. Time to second progression also improved (25.7 vs 19.1 months), and an overall‑survival trend favored the experimental arm, suggesting a meaningful clinical benefit for a population that historically experiences rapid relapse.

The CHMP’s positive opinion clears a regulatory hurdle for EU approval, positioning camizestrant as the first oral SERD approved for ESR1‑mutated breast cancer. With U.S. and Japanese reviews now active, market entry could reshape the treatment algorithm, offering oncologists a targeted oral option that may delay chemotherapy and improve quality of life. Investors will watch closely as the drug moves toward potential approval, anticipating revenue streams that complement AstraZeneca’s existing oncology portfolio and address an unmet need in advanced breast cancer care.